Curocell

Curocell Share Buybacks

The Share Buybacks of Curocell (372320.KQ) as of Oct 27, 2026 is 1.56 B KRW. In the previous year, Share Buybacks was 32.18 B KRW — a change of -95.17% (lower).

Share Buybacks

1.56 BKRW

YoY

-95.17%

Last updated:

Share Buybacks of Curocell is 2024 1.56 B KRW. Share Buybacks of Curocell was 2023 32.18 B KRW. It decreases by -95.17% lower compared to the previous year.

The Curocell Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2022
54.14 M KRW
Jan 1, 2023
32.18 B KRW
Jan 1, 2024
1.56 B KRW
The Curocell Share Buybacks history
YEARShare BuybacksYoY
1.56 BKRW-95.17%
32.18 BKRW+59,343.95%
54.14 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curocell Stock analysis

What does Curocell do? Curocell Inc makes money through the development and commercialization of CAR-T therapy technologies for cancer treatment. The company focuses on novel chimeric antigen receptor (CAR)-T therapies targeting specific cancer antigens, improving medicinal effects, reducing side effects, and automating quality analysis. These products are developed for pharmaceutical companies and healthcare providers seeking advanced cancer treatments. The firm's R&D efforts target the biotechnology sector, specifically oncology applications. Curocell Inc's business model centers on creating innovative CAR-T therapies that address unmet medical needs in cancer care. The company's research and development activities are directed at enhancing the efficacy and safety of CAR-T treatments, which are sold to pharmaceutical firms for further development and distribution. The firm's products are positioned within the biotechnology industry, catering to the growing demand for targeted cancer therapies. The company's revenue streams come from the sale of its developed CAR-T technologies to pharmaceutical partners. These partnerships enable the commercialization of Curocell's innovations in the global oncology market. Curocell Inc operates within the biotechnology sector, specifically focusing on the development of next-generation CAR-T therapies for cancer patients. Curocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curocell stock

Share Buybacks of Curocell is 1.56 B KRW in 2024.

Share Buybacks of Curocell changed from 32.18 B KRW to 1.56 B KRW, representing a -95.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks Curocell since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Curocell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Curocell

All Key Metrics — Curocell